What has changed in the current management of hypertension from the renal point of view?;Qué ha cambiado en el manejo actual de la hipertensión arterial desde el punto de vista renal?

Revista Clinica Espanola

Volumn 210, Issue SUPPL. 1, 2010, Pages 12-17

  Diez J ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

Author keywords

Albuminuria; Blood pressure; Chronic kidney disease; Glomerular filtration; Hypertension

Indexed keywords

ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; DIABETIC PATIENT; HIGH RISK PATIENT; HUMAN; HYPERTENSION; KIDNEY FUNCTION; KIDNEY INJURY; PRACTICE GUIDELINE; RENAL SYSTEM PARAMETERS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

HUMANS; HYPERTENSION; KIDNEY DISEASES; PRACTICE GUIDELINES AS TOPIC;

EID: 79551565297     PISSN: 00142565     EISSN: 15781860     Source Type: Journal    
DOI: 10.1016/S0014-2565(10)70003-5     Document Type: Article

References (49)

1. G. Mancia, G. De Backer, A. DominiczaK, R. Cifkova, R. Fagard, and G. Germano 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) J Hypertens 25 2007 1105 1187 (Pubitemid 46924065)
2. C. Cuspidi Cardio-renal organ damage and cardiovascular outcomes in hypertension J Hypertens 27 2009 702 706
3. B.F. Culleton, M.G. Larson, P.W. Wilson, J.C. Evans, P.S. Parfrey, and D. Levy Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency Kidney Int 56 1999 2214 2219
4. J. Arnlöv, J.C. Evans, J.B. Meigs, T.J. Wang, C.S. Fox, and D. Levy Low-grade albuminuria and incidente of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study Circulation 112 2005 969 975
5. H.L. Hillege, V. Fidler, G.F. Diercks, W.H. Van Gilst, D. De Zeeuw, and D.J. Van Veldhuisen Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population Circulation 106 2002 1777 1782
6. R.M. Conroy, K. Pyörälä, A.P. Fitzgerald, S. Sans, A. Menotti, and G. De Backer Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project Eur Heart J 24 2003 987 1003
7. M. Cirillo, M.P. Lanti, A. Menotti, M. Laurenzi, M. Mancini, A. Zanchetti, and N.G. De Santo Definition of kidney dysfunction as a cardiovascular risk factor: use of urinary albumin excretion and estimated glomerular filtration rate Arch Intern Med 168 2008 617 624
8. C. Tsioufis, E. Vezali, D. Tsiachris, K. Dimitriadis, E. Taxiarchou, and D. Chatzis Left ventricular hypertrophy versus chronic kidney disease as predictors of cardiovascular events in hypertension: a Greek 6-year-follow-up-study J Hypertens 27 2009 744 752
9. F. Viazzi, G. Leoncin, N. Conti, C. Tomolillo, G. Giachero, and M. Vercilli Combined effect of albuminuria and estimated glomerular filtration rate on cardiovascular events and all-cause mortality in uncomplicated hypertensive patients J Hypertens 28 2010 848 855
10. L.M. Ruilope, A. Zanchetti, S. Julios, G.T. McInnes, J. Segura, and P. Stolt Prediction of cardiovascular outcome by estimated glomerular filtration rate and estimated creatinine clearance in the high-risk hipertensión population of the VALUE trial J Hypertens 25 2007 1473 1479
11. T. Ninomiya, V. Perkovic, B.E. De Galan, S. Zoungas, A. Pillai, and M. Jardine Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes J Am Soc Nephrol 20 2009 1813 1821
12. B. Waeber, A. De la Sierra, and L.M. Ruilope Target organ damage: how to detect it and how to treat it? J Hypertens 27 Suppl 3 2009 S13 S18
13. D. De Zeeuw Albuminuria: a target for treatment of type 2 diabetic nephropaty Semin Nephrol 27 2007 172 181
14. T. Sehestedt, J. Jeppesen, T.W. Hansen, S. Rasmussen, K. Wachtell, and H. Ibsen Wich markers of subclinical organ damage to measure in individuals with high normal blood pressure? J Hypertens 27 2009 1165 1171
15. A.V. Chobanian, G.L. Bakris, H.R. Black, W.C. Cushman, L.A. Green, and J.L. Izzo Jr. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure Hypertension 42 2003 1206 1252
16. Kidney Disease Outcomes Quality Initiative (K/DOQI) K/DOQI clinical practice guidelines on hypertension ans antihypertensive agents in chronic kidney disease Am J Kidney Dis 43 5 Suppl 1 2004 S1 S290
17. H.J. Heerspink, T. Ninomiya, S. Zoungas, D. De Zeeuw, D.E. Grobbee, and M.J. Jardine Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials Lancet 373 2009 1009 1015
18. A. Zanchetti, G. Grassi, and G. Mancia When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical reappraisal J Hypertens 27 2009 923 934
19. T. Berl, L.G. Hunsicker, J.B. Lewis, M.A. Pfeffer, J.G. Porush, and J.L. Rouleau Impact of achieved blood pressure on cardiovascular outcomes in the iIrbesartan Diabetic Nephropathy Trial J Am Soc Nephrol 16 2005 2170 2179
20. M.A. Pohl, S. Blumenthal, D.J. Cordonnier, F. De Alvaro, G. Deferrari, and G. Eisner Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the Irbesartan Diabetic Nephropathy Trial: clinical implications and limitations J Am Soc Nephrol 19 2005 3027 3037
21. B.E. De Galan, V. Perkovic, T. Ninomiya, A. Pillai, A. Patel, and A. Cass Lowering blood pressure reduces renal events in type 2 diabetes J Am Soc Nephrol 20 2009 883 892
22. S. Yusuf, H.C. Diener, R.L. Sacco, D. Cotton, S. Ounpuu, and W.A. Lawton Telmisartan to prevent recurrent stroke and cardiovascular events N Engl J Med 359 2008 1225 1237
23. Telmisartan Randomised AssessmeNt study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators Effects of the angiotensin-receptor blocker telmisartan on cardiovascular eventa in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial Lancet 372 2008 1174 1183
24. F.H. Messerli, G. Mancia, C.R. Conti, A.C. Hewkin, and S. Kupfer Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Intern Med 144 2006 884 893
25. P. Sleight, J. Redon, P. Verdecchia, G. Mancia, and P. Gao Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study J Hypertens 27 2009 1360 1369
26. S. Bangalore, F.H. Messerli, C. Wun, A.L. Zuckerman, D. DeMicco, and J.B. Kostis J-Curve revisited: an analysis of the Treating to New Targets (TNT) Trial J Am Coll Cardiol 53 2009 A217
27. F.H. Messerli, and G.S. Panjrath The J-curve between blood pressure and coronary artery disease or Essentials hipertensión: exactly essential? J Am Coll Cardiol 54 2009 1827 1834
28. F.G. Have, R. Venkataraman, G.J. Zoghbi, G.J. Perry, A.M. DeMattos, and A.E. Iskandran The scope of coronary heart disease in patients with chronic kidney disease J Am Coll Cardiol 53 2009 2129 2140
29. K. Hopkins, and G.L. Bakris Hypertension goals in advanced-stage kidney disease Clin J Am Soc Nephrol 4 Suppl 1 2009 S92 S94
30. B.J. Hoogwerf Renin-angiotensin system blockade and cardiovascular and renal protection Am J Cardiol 105 1 Suppl 2010 30A A35
31. H.J. Lambers Heerspink, V. Perkovic, and D. De Zeeuw Renal and cardio- protective effects of direct renin inhibition: a systematic literature review J Hypertens 27 2009 2321 2331
32. J.H. Song, S.H. Cha, S.B. Hong, and D.H. Kim Dual blockade of the reninangiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in chronic kidney disease J Hypertens Suppl 24 2006 S101 S106
33. S. Yusuf, K.K. Teo, J. Pogue, L. Dyal, I. Copland ONTARGET investigators Telmisartan, ramipril, or both in patients at high risk for vascular events N Engl J Med 358 2008 1547 1559
34. J.F. Mann, R.E. Schmieder, M. McQueen, L. Dyal, H. Schumacher, and J. Pogue Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial Lancet 372 2008 547 553
35. P. Verdecchia, P. Sleight, G. Mancia, R. Fagard, B. Trimarco, and R. Schmieder Effects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease Circulation 120 2009 1380 1389
36. B.R. Cowan, A.A. Young, C. Anderson, R.N. Doughty, R. Krittayaphong, and E. Lonn Left ventricular mass and volume with telmisartan, ramipril, or combination in patients with previous atherosclerotic events or with diabtes mellitus (from the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial [ONTARGET]) Am J Cardiol 104 2009 1484 1489
37. C.O. Phillips, A. Kashani, D.K. Ko, G. Francis, and H.M. Krumholz Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction Arch Intern Med 167 2007 1930 1936
38. N. Nakao, A. Yoshimura, H. Morita, M. Takada, T. Kayano, and T. Ideura Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in nondiabetic renal disease (COOPERATE): a randomised controlled trial Lancet 361 2003 117 124 (Pubitemid 36092015)
39. J.A. Staessen, Y. Li, and T. Richart Oral renin inhibitors Lancet 346 2006 1449 1456
40. S. Oparil, S.A. Yarrows, S. Patel, H. Fang, J. Zhang, and A. Satlin Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised double-blind trial Lancet 370 2007 221 229
41. Y. Uresin, A.A. Taylor, C. Kilo, D. Tschöpe, M. Santonastaso, and G. Ibram Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension J Ren Angiotens Aldost Syst 8 2007 190 198
42. H. Geiger, E. Barranco, M. Gorostidi, A. Taylor, X. Zhang, and Z. Xiang Combination therapy with various combinations of aliskiren, valsartan, and hydrochlorothiazide in hypertensive patients not adequately responsive to hydrochlorothiazide alone J Clin Hypertens 11 2009 324 332
43. J.J.V. McMurray, B. Pitt, R. Latini, A.P. Maggioni, S.D. Solomon, and D.L. Keefe Effect of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure Circ Heart Fail 1 2008 17 24
44. H.H. Parving, F. Persson, J.B. Lewis, E.J. Lewis, N.K. Hollenberg for the AVOID Study Investigators Aliskiren combined with losartan in type 2 diabetes and nephropathy N Engl J Med 358 2008 2433 2446
45. S.D. Solomon, E. Appelbaum, W.J. Manning, A. Verma, T. Berglund, and V. Lukashevich Effect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy Circulation 119 2009 530 537
46. M.A. Pfeffer, K. Swedberg, and C.B. Granger Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programe Lancer 362 9386 2003 759 766 (Pubitemid 37093915)
47. G. Mancia, S. Laurent, E. Agabiti-Rosei, E. Ambrosioni, M. Burnier, and M.J. Caulfield Reappraisal of European guidelines on hypertension management: a European Society of Hypertension task Force document J Hypertens 27 2009 2121 2158
48. J.A. Staessen, T. Richart, Z. Wang, and L. Thijs Implications of recently published trials of blood pressure-lowering drugs in hypertensive or high-risk patients Hypertension 55 2010 819 831
49. S.C. Smith Jr. Screening for high-risk cardiovascular disease Arch Intern Med 170 2010 40 42